PUBLISHER: Allied Market Research | PRODUCT CODE: 1566764
PUBLISHER: Allied Market Research | PRODUCT CODE: 1566764
Spine Biologics Market By Product (Spinal Allografts, Bone Graft Substitutes, Cell-Based Matrix) , By End User (Hospitals, Outpatient Facilities) : Global Opportunity Analysis and Industry Forecast, 2024-2033
Spine Biologics Market
The spine biologics market was valued at $3.05 billion in 2023 and is estimated to reach $5.55 billion by 2035, exhibiting a CAGR of 5.29% from 2024 to 2035.
Spine biologics comprises of materials that enhance spinal fusion, promote healing, and treat several spinal disorders. The materials involve growth factors, stem cells, and bone grafts, which help in the natural healing processes of the body. Bone grafts are the scaffolds required for new bone growth. They include autografts, which belong to patient's own body, and allografts, which are derived from a donor. Stem cells are a special form of cells that have the ability to generate new cells with complete functionalities and growth factors, such as bone morphogenetic proteins (BMPs), play role in stimulating the cells for regeneration and bone repair. The usage of spine biologics is widespread in spinal fusion surgeries, which involve the joining of two or more vertebrae.
Increase in the prevalence of spinal disorders, particularly in the exponentially growing geriatric population, is a key driver of the spine biologics market. In addition, with rising inclination toward minimally invasive procedures, the demand for spine biologics is surging as they facilitate minimal invasion during spinal surgeries and promote healing. In recent times, the use of additive manufacturing for the development of bone graft substitute is an emerging trend in the market. These substitutes offer equivalent efficacy and improved safety when compared to bone grafts, which hold the potential for rejection by the body.
However, the development of spine biologics is a complex procedure with high expenses, hence restraining the development of the market. Furthermore, the ineffective reimbursement policies that do not offer adequate cover for spinal surgeries deter individuals from undergoing expensive treatments, hence limiting the market growth. On the contrary, the consistently rising numbers of spinal injuries are anticipated to propel the demand for spine biologics in the future. The National Library of Medicine recently published an article which reported that every year 38% of new spinal cord injuries occur due to motor vehicular crashes in the U.S. falling is the second most prevalent reason for spinal injuries, accounting for 30% of the total count.
Segment Review
The spine biologics market is segmented into product, end user, and region. By product, the market is divided into spinal allografts, bone graft substitutes, and cell-based matrix. As per end user, it is bifurcated into hospitals and outpatient facilities. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Findings
By product, the spinal allografts segment dominated the market in 2023.
As per end user, the hospital segment acquired a high stake in the market in 2023.
Region wise, North America is projected to be the highest revenue generator by 2035.
Competition Analysis
The major players operating in the spine biologics market are Stryker, NuVasive, Inc., Orthofix, Johnson & Johnson, Exactech, Inc., Zimmer Biomet. Arthrex, Inc., Medtronic Plc, Organogenesis Inc., and Kuros Biosciences. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.
Additional benefits you will get with this purchase are:
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)
- Regulatory Guidelines
- Additional company profiles with specific to client's interest
- Additional country or region analysis- market size and forecast
- Expanded list for Company Profiles
- Historic market data
- Key player details (including location, contact details, supplier/vendor network etc. in excel format)
Key Market Segments
By Product
- Spinal Allografts
- Bone Graft Substitutes
- Cell-Based Matrix
By End User
- Hospitals
- Outpatient Facilities
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players:
- Stryker Corporation
- NuVasive, Inc.
- orthofix
- Johnson & Johnson
- Exactech, Inc
- Zimmer Biomet Holding, Inc.
- Arthrex, Inc.
- Medtronic plc
- Organogenesis Inc
- Kuros Biosciences
TABLE OF CONTENTS
CHAPTER 1: INTRODUCTION
- 1.1. Report Description
- 1.2. Key Market Segments
- 1.3. Key Benefits
- 1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models
CHAPTER 2: EXECUTIVE SUMMARY
- 2.1. CXO Perspective
CHAPTER 3: MARKET LANDSCAPE
- 3.1. Market Definition and Scope
- 3.2. Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
- 3.3. Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
- 3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities
CHAPTER 4: SPINE BIOLOGICS MARKET, BY PRODUCT
- 4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Product
- 4.2. Spinal Allografts
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
- 4.3. Bone Graft Substitutes
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country
- 4.4. Cell-Based Matrix
- 4.4.1. Key Market Trends, Growth Factors and Opportunities
- 4.4.2. Market Size and Forecast, By Region
- 4.4.3. Market Share Analysis, By Country
CHAPTER 5: SPINE BIOLOGICS MARKET, BY END USER
- 5.1. Market Overview
- 5.1.1 Market Size and Forecast, By End User
- 5.2. Hospitals
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
- 5.3. Outpatient Facilities
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country
CHAPTER 6: SPINE BIOLOGICS MARKET, BY REGION
- 6.1. Market Overview
- 6.1.1 Market Size and Forecast, By Region
- 6.2. North America
- 6.2.1. Key Market Trends and Opportunities
- 6.2.2. Market Size and Forecast, By Product
- 6.2.3. Market Size and Forecast, By End User
- 6.2.4. Market Size and Forecast, By Country
- 6.2.5. U.S. Spine Biologics Market
- 6.2.5.1. Market Size and Forecast, By Product
- 6.2.5.2. Market Size and Forecast, By End User
- 6.2.6. Canada Spine Biologics Market
- 6.2.6.1. Market Size and Forecast, By Product
- 6.2.6.2. Market Size and Forecast, By End User
- 6.2.7. Mexico Spine Biologics Market
- 6.2.7.1. Market Size and Forecast, By Product
- 6.2.7.2. Market Size and Forecast, By End User
- 6.3. Europe
- 6.3.1. Key Market Trends and Opportunities
- 6.3.2. Market Size and Forecast, By Product
- 6.3.3. Market Size and Forecast, By End User
- 6.3.4. Market Size and Forecast, By Country
- 6.3.5. Germany Spine Biologics Market
- 6.3.5.1. Market Size and Forecast, By Product
- 6.3.5.2. Market Size and Forecast, By End User
- 6.3.6. France Spine Biologics Market
- 6.3.6.1. Market Size and Forecast, By Product
- 6.3.6.2. Market Size and Forecast, By End User
- 6.3.7. UK Spine Biologics Market
- 6.3.7.1. Market Size and Forecast, By Product
- 6.3.7.2. Market Size and Forecast, By End User
- 6.3.8. Italy Spine Biologics Market
- 6.3.8.1. Market Size and Forecast, By Product
- 6.3.8.2. Market Size and Forecast, By End User
- 6.3.9. Spain Spine Biologics Market
- 6.3.9.1. Market Size and Forecast, By Product
- 6.3.9.2. Market Size and Forecast, By End User
- 6.3.10. Rest of Europe Spine Biologics Market
- 6.3.10.1. Market Size and Forecast, By Product
- 6.3.10.2. Market Size and Forecast, By End User
- 6.4. Asia-Pacific
- 6.4.1. Key Market Trends and Opportunities
- 6.4.2. Market Size and Forecast, By Product
- 6.4.3. Market Size and Forecast, By End User
- 6.4.4. Market Size and Forecast, By Country
- 6.4.5. Japan Spine Biologics Market
- 6.4.5.1. Market Size and Forecast, By Product
- 6.4.5.2. Market Size and Forecast, By End User
- 6.4.6. China Spine Biologics Market
- 6.4.6.1. Market Size and Forecast, By Product
- 6.4.6.2. Market Size and Forecast, By End User
- 6.4.7. Australia Spine Biologics Market
- 6.4.7.1. Market Size and Forecast, By Product
- 6.4.7.2. Market Size and Forecast, By End User
- 6.4.8. India Spine Biologics Market
- 6.4.8.1. Market Size and Forecast, By Product
- 6.4.8.2. Market Size and Forecast, By End User
- 6.4.9. South Korea Spine Biologics Market
- 6.4.9.1. Market Size and Forecast, By Product
- 6.4.9.2. Market Size and Forecast, By End User
- 6.4.10. Rest of Asia-Pacific Spine Biologics Market
- 6.4.10.1. Market Size and Forecast, By Product
- 6.4.10.2. Market Size and Forecast, By End User
- 6.5. LAMEA
- 6.5.1. Key Market Trends and Opportunities
- 6.5.2. Market Size and Forecast, By Product
- 6.5.3. Market Size and Forecast, By End User
- 6.5.4. Market Size and Forecast, By Country
- 6.5.5. Brazil Spine Biologics Market
- 6.5.5.1. Market Size and Forecast, By Product
- 6.5.5.2. Market Size and Forecast, By End User
- 6.5.6. Saudi Arabia Spine Biologics Market
- 6.5.6.1. Market Size and Forecast, By Product
- 6.5.6.2. Market Size and Forecast, By End User
- 6.5.7. South Africa Spine Biologics Market
- 6.5.7.1. Market Size and Forecast, By Product
- 6.5.7.2. Market Size and Forecast, By End User
- 6.5.8. Rest of LAMEA Spine Biologics Market
- 6.5.8.1. Market Size and Forecast, By Product
- 6.5.8.2. Market Size and Forecast, By End User
CHAPTER 7: COMPETITIVE LANDSCAPE
- 7.1. Introduction
- 7.2. Top Winning Strategies
- 7.3. Product Mapping of Top 10 Player
- 7.4. Competitive Dashboard
- 7.5. Competitive Heatmap
- 7.6. Top Player Positioning, 2023
CHAPTER 8: COMPANY PROFILES
- 8.1. Stryker Corporation
- 8.1.1. Company Overview
- 8.1.2. Key Executives
- 8.1.3. Company Snapshot
- 8.1.4. Operating Business Segments
- 8.1.5. Product Portfolio
- 8.1.6. Business Performance
- 8.1.7. Key Strategic Moves and Developments
- 8.2. NuVasive, Inc.
- 8.2.1. Company Overview
- 8.2.2. Key Executives
- 8.2.3. Company Snapshot
- 8.2.4. Operating Business Segments
- 8.2.5. Product Portfolio
- 8.2.6. Business Performance
- 8.2.7. Key Strategic Moves and Developments
- 8.3. Orthofix
- 8.3.1. Company Overview
- 8.3.2. Key Executives
- 8.3.3. Company Snapshot
- 8.3.4. Operating Business Segments
- 8.3.5. Product Portfolio
- 8.3.6. Business Performance
- 8.3.7. Key Strategic Moves and Developments
- 8.4. Johnson And Johnson
- 8.4.1. Company Overview
- 8.4.2. Key Executives
- 8.4.3. Company Snapshot
- 8.4.4. Operating Business Segments
- 8.4.5. Product Portfolio
- 8.4.6. Business Performance
- 8.4.7. Key Strategic Moves and Developments
- 8.5. Exactech, Inc
- 8.5.1. Company Overview
- 8.5.2. Key Executives
- 8.5.3. Company Snapshot
- 8.5.4. Operating Business Segments
- 8.5.5. Product Portfolio
- 8.5.6. Business Performance
- 8.5.7. Key Strategic Moves and Developments
- 8.6. Zimmer Biomet Holding, Inc.
- 8.6.1. Company Overview
- 8.6.2. Key Executives
- 8.6.3. Company Snapshot
- 8.6.4. Operating Business Segments
- 8.6.5. Product Portfolio
- 8.6.6. Business Performance
- 8.6.7. Key Strategic Moves and Developments
- 8.7. Arthrex, Inc.
- 8.7.1. Company Overview
- 8.7.2. Key Executives
- 8.7.3. Company Snapshot
- 8.7.4. Operating Business Segments
- 8.7.5. Product Portfolio
- 8.7.6. Business Performance
- 8.7.7. Key Strategic Moves and Developments
- 8.8. Medtronic Plc
- 8.8.1. Company Overview
- 8.8.2. Key Executives
- 8.8.3. Company Snapshot
- 8.8.4. Operating Business Segments
- 8.8.5. Product Portfolio
- 8.8.6. Business Performance
- 8.8.7. Key Strategic Moves and Developments
- 8.9. Organogenesis Inc
- 8.9.1. Company Overview
- 8.9.2. Key Executives
- 8.9.3. Company Snapshot
- 8.9.4. Operating Business Segments
- 8.9.5. Product Portfolio
- 8.9.6. Business Performance
- 8.9.7. Key Strategic Moves and Developments
- 8.10. Kuros Biosciences
- 8.10.1. Company Overview
- 8.10.2. Key Executives
- 8.10.3. Company Snapshot
- 8.10.4. Operating Business Segments
- 8.10.5. Product Portfolio
- 8.10.6. Business Performance
- 8.10.7. Key Strategic Moves and Developments
